These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 1515641)

  • 1. Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model.
    Imura Y; Stassen JM; Bunting S; Stockmans F; Collen D
    Blood; 1992 Sep; 80(5):1247-53. PubMed ID: 1515641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis.
    Collen D; Lu HR; Stassen JM; Vreys I; Yasuda T; Bunting S; Gold HK
    Thromb Haemost; 1994 Jan; 71(1):95-102. PubMed ID: 8165652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
    Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D
    Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.
    Yasuda T; Gold HK; Kohmura C; Guerrero L; Yaoita H; Fallon JT; Bunting S; Collen D
    Arterioscler Thromb; 1993 May; 13(5):738-47. PubMed ID: 8485125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs.
    Lu HR; Gold HK; Wu Z; Yasuda T; Pauwels P; Rapold HJ; Napier M; Bunting S; Collen D
    Thromb Haemost; 1992 Jun; 67(6):686-91. PubMed ID: 1509410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.
    Sabatine MS; Tu TM; Jang IK
    J Thromb Thrombolysis; 2000 Oct; 10(2):189-96. PubMed ID: 11005941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro.
    Samanen J; Ali F; Romoff T; Calvo R; Sorenson E; Vasko J; Storer B; Berry D; Bennett D; Strohsacker M
    J Med Chem; 1991 Oct; 34(10):3114-25. PubMed ID: 1920361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic RGD peptide analogues as antiplatelet antithrombotics.
    Barker PL; Bullens S; Bunting S; Burdick DJ; Chan KS; Deisher T; Eigenbrot C; Gadek TR; Gantzos R; Lipari MT
    J Med Chem; 1992 May; 35(11):2040-8. PubMed ID: 1597855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
    Varon D; Lider O; Dardik R; Shenkman B; Alon R; Hershkoviz R; Kapustina G; Savion N; Martinowitz U; Greenspoon N
    Thromb Haemost; 1993 Dec; 70(6):1030-6. PubMed ID: 8165596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403.
    Katada J; Takiguchi Y; Muramatsu M; Fujiyoshi T; Uno I
    Thromb Res; 1997 Oct; 88(1):27-40. PubMed ID: 9336871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
    Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
    Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model.
    Cadroy Y; Houghten RA; Hanson SR
    J Clin Invest; 1989 Sep; 84(3):939-44. PubMed ID: 2760221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749).
    Nicholson NS; Panzer-Knodle SG; Salyers AK; Taite BB; King LW; Miyano M; Gorczynski RJ; Williams MH; Zupec ME; Tjoeng FS
    J Pharmacol Exp Ther; 1991 Mar; 256(3):876-82. PubMed ID: 2005585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis.
    Willette RN; Sauermelch CF; Rycyna R; Sarkar S; Feuerstein GZ; Nichols AJ; Ohlstein EH
    Stroke; 1992 May; 23(5):703-11. PubMed ID: 1605806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide inhalation inhibits platelet aggregation and platelet-mediated pulmonary thrombosis in rats.
    Nong Z; Hoylaerts M; Van Pelt N; Collen D; Janssens S
    Circ Res; 1997 Nov; 81(5):865-9. PubMed ID: 9351461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved potency and specificity of Arg-Gly-Asp (RGD) containing peptides as fibrinogen receptor blocking drugs.
    Foster MR; Hornby EJ; Brown S; Kitchin J; Hann M; Ward P
    Thromb Res; 1993 Nov; 72(3):231-45. PubMed ID: 8303662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.